R&D in the "Decade of Vaccines":

From the "Decade of Vaccines Collaboration" to the Global Vaccine & Immunization Research Forum

B. Fenton Hall, MD, PhD Chief, Parasitology & International Programs Branch Division of Microbiology and Infectious Diseases NIAID, NIH, DHHS

On Behalf of the DoV Collaborating Agencies



GVIRF 4-6 March 2014



National Institute of Allergy and Infectious Diseases

Why a "Decade of Vaccines"?

Significant impact of immunization in the past decades

- > Progress with disease elimination or eradication
- Millions of deaths averted

Ability to deliver immunization with high coverage

- > Already reaching >80% children globally
- Higher than any other intervention across the continuum of care

Increasing number of diseases now vaccine preventable

- Robust vaccine pipeline
- Progress with adding vaccines into national programs

Despite many successes, opportunities to do much better

Mission of the Decade of Vaccines



"ATTAINMENT OF A WORLD IN WHICH ALL PEOPLE AT RISK ARE PROTECTED AGAINST VACCINE-PREVENTABLE DISEASES"



In 2010 a Decade of Vaccines Collaboration (DoVC) was established to coordinate the development of a Global Vaccine Action Plan to provide a framework for accomplishing the mission.


DoV Leadership Council



DR. SETH BERKLEY CEO GAVI Alliance



DR. MARGARET CHAN Director General WHO



DR. CHRISTOPHER ELIAS President, Global Development Program (effective Feb. 1, 2012) Bill and Melinda Gates Foundation



DR. ANTHONY FAUCI Director NIAID



DR. ANTHONY LAKE Executive Director UNICEF




MS. JOY PHUMAPHI Executive Secretary African Leaders Malaria Alliance

Outputs of the Decade of Vaccines Collaboration



Global Vaccine Action Plan

2011–2020



The Official Journal of the Edward Jenner Society The Official Journal of the International Society for Vaccines The Official Journal of the Japanese Society for Vaccinology

Decade of Vaccines: Vision & Mission



Global Vaccine Action Plan "We envision a world in which all individuals and communities enjoy lives free from vaccine-preventable diseases.

The mission of the Decade of Vaccines is to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live."

The GVAP Differs Significantly from Prior Vaccine Initiatives



Global Vaccine Action Plan

Explicitly includes an R&D component

- Basic & Translational
- Implementation
- Operational
- Explicitly includes an M&E/ Accountability component and framework

World Health Assembly Actions

- Endorsed the GVAP in May 2012 and urged 194 member states to:
 - > Apply
 - Commit
 - Report
 - Annually to WHO regional and global governing bodies
 - > Regional Committees (Q3-Q4)
 - > WHO Executive Board (January)
 - > WHA (May)

Supported the M&E/ Accountability Framework in May 2013




"Decade of Vaccines" Supplement

(Vaccine 31, Suppl. 2, 18 April 2013)

- 27 Articles, 210 Authors, 90 Reviewers
- Addresses GVAP Goals and Strategic Objectives
- 9 Case Studies, including:

Epstein-Barr Virus, Cytomegalovirus, HIV, Respiratory Syncytial Virus, Group A Streptococci, Tuberculosis, Hookworm, Malaria, Leishmaniasis



www.sciencedirect.com/science/journal/0264410X/31/supp/S2 (open source)

R&D Reporting

Scheduled to take place every 2 years

Key areas relate to Strategic Objective 6 and Goal 4 of the GVAP:

- > Expanding capabilities and engagement with end-users;
- > Enabling development of new vaccines;
- Accelerating development, licensing and uptake of vaccines; and
- > Improving programme efficiencies and increasing coverage.

R&D Reporting

Enhanced Collaboration on Research Matters Related to the Global Vaccine Action Plan"

- Memorandum of Understanding signed March 20, 2013 by BMGF, NIAID and WHO
- Provides framework for enhanced collaboration on R&D related to the GVAP

Global Vaccine & Immunization Research Forum

- > 4-6 March 2014, Bethesda MD, USA
- First of an ongoing series